AMGNAmgenSigning up patients
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Advanced Solid Tumors
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 14 (planned)
- Started
- Jan 2, 2026
- Main results expected
- Jul 1, 2028
- Fully finished
- Jul 1, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Measured over: Up to approximately 18 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07172919 · record last updated 2026-07-23 · checked 2026-11-09 15:47 UTC